There is one clinical trial.
The study is configured as a retrospective and prospective observational study. The study will be multi-center and will involve all COVID-19 pneumonia patients treated with canakinumab administered subcutaneously.
Description: percentage of patients treated with canakinumab sc who do not require intensive care treatment during hospitalization for COVID-19Measure: intensive care treatment Time: 9 months
Description: ICU stay timesMeasure: ICU stay times Time: 9 months
Description: percentage of patients who died 1 month after treatmentMeasure: % died after 1 month after treatment Time: 9 months
Description: time of hospitalizationMeasure: hospitalization Time: 9 months
Description: number of adverse eventMeasure: adverse event Time: 9 months